The Epstein-Barr Virus Encoded BART miRNAs Potentiate Tumor Growth


Epstein-Barr virus is a herpes virus that persistently infects essentially every human being for life. It also has the ability to latently infect B lymphocytes and cause them to proliferate indefinitely in culture, and is associated with several forms of carcinoma and lymphoma. The virus contains genes for ~30 miRNAs in its BART region. The functions of these miRNAs are mostly unknown, but it is clear that they are not required to drive the growth of infected cells in vitro. We have shown previously, however, that these miRNAs are all highly expressed in the EBV associated cancers and that their expression is deregulated suggesting they may play a role in vivo. Until now, the significance of BART miRNAs to tumor development in vivo was unknown. Here we have used a mouse xenograft model to show that these miRNAs, while having little or no discernible effect on the growth of infected cells in vitro, potentiate the seeding and growth of EBV associated tumors in vivo.


Vyšlo v časopise: The Epstein-Barr Virus Encoded BART miRNAs Potentiate Tumor Growth. PLoS Pathog 11(1): e32767. doi:10.1371/journal.ppat.1004561
Kategorie: Research Article
prolekare.web.journal.doi_sk: 10.1371/journal.ppat.1004561

Souhrn

Epstein-Barr virus is a herpes virus that persistently infects essentially every human being for life. It also has the ability to latently infect B lymphocytes and cause them to proliferate indefinitely in culture, and is associated with several forms of carcinoma and lymphoma. The virus contains genes for ~30 miRNAs in its BART region. The functions of these miRNAs are mostly unknown, but it is clear that they are not required to drive the growth of infected cells in vitro. We have shown previously, however, that these miRNAs are all highly expressed in the EBV associated cancers and that their expression is deregulated suggesting they may play a role in vivo. Until now, the significance of BART miRNAs to tumor development in vivo was unknown. Here we have used a mouse xenograft model to show that these miRNAs, while having little or no discernible effect on the growth of infected cells in vitro, potentiate the seeding and growth of EBV associated tumors in vivo.


Zdroje

1. Kieff E, Rickinson A (2007) Epstein-Barr Virus. In: Fields’ virology. Knipe DM, Howley PM, editors. Philadelphia: Wolters kluwer/Lippincott Williams & Wilkins.

2. Thorley-Lawson DA, Babcock GJ (1999) A model for persistent infection with Epstein-Barr virus: the stealth virus of human B cells. Life sciences 65: 1433–1453. doi: 10.1016/S0024-3205(99)00214-3 10530796

3. Babcock GJ, Thorley-Lawson DA (2000) Tonsillar memory B cells, latently infected with Epstein-Barr virus, express the restricted pattern of latent genes previously found only in Epstein-Barr virus-associated tumors. Proceedings of the National Academy of Sciences of the United States of America 97: 12250–12255. doi: 10.1073/pnas.200366597 11035774

4. Thorley-Lawson DA, Gross A (2004) Persistence of the Epstein-Barr virus and the origins of associated lymphomas. The New England journal of medicine 350: 1328–1337. doi: 10.1056/NEJMra032015 15044644

5. Gregory CD, Rowe M, Rickinson AB (1990) Different Epstein-Barr virus-B cell interactions in phenotypically distinct clones of a Burkitt’s lymphoma cell line. The Journal of general virology 71 (Pt 7): 1481–1495. doi: 10.1099/0022-1317-71-7-1481 2165133

6. Rowe M, Rowe DT, Gregory CD, Young LS, Farrell PJ, et al. (1987) Differences in B cell growth phenotype reflect novel patterns of Epstein-Barr virus latent gene expression in Burkitt’s lymphoma cells. The EMBO journal 6: 2743–2751. 2824192

7. Hochberg D, Middeldorp JM, Catalina M, Sullivan JL, Luzuriaga K, et al. (2004) Demonstration of the Burkitt’s lymphoma Epstein-Barr virus phenotype in dividing latently infected memory cells in vivo. Proceedings of the National Academy of Sciences of the United States of America 101: 239–244. doi: 10.1073/pnas.2237267100 14688409

8. Kirchmaier AL, Sugden B (1995) Plasmid maintenance of derivatives of oriP of Epstein-Barr virus. J Virol 69: 1280–1283. 7815506

9. Leight ER, Sugden B (2001) Establishment of an oriP replicon is dependent upon an infrequent, epigenetic event. Molecular and cellular biology 21: 4149–4161. doi: 10.1128/MCB.21.13.4149-4161.2001 11390644

10. Middleton T, Sugden B (1994) Retention of plasmid DNA in mammalian cells is enhanced by binding of the Epstein-Barr virus replication protein EBNA1. Journal of virology 68: 4067–4071. 8189545

11. Yates JL, Warren N, Sugden B (1985) Stable replication of plasmids derived from Epstein-Barr virus in various mammalian cells. Nature 313: 812–815. doi: 10.1038/313812a0 2983224

12. Chodosh J, Holder VP, Gan YJ, Belgaumi A, Sample J, et al. (1998) Eradication of latent Epstein-Barr virus by hydroxyurea alters the growth-transformed cell phenotype. The Journal of infectious diseases 177: 1194–1201. doi: 10.1086/515290 9593003

13. Hammerschmidt W, Sugden B (2004) Epstein-Barr virus sustains Burkitt’s lymphomas and Hodgkin’s disease. Trends Mol Med 10: 331–336. doi: 10.1016/j.molmed.2004.05.006 15242681

14. Kennedy G, Komano J, Sugden B (2003) Epstein-Barr virus provides a survival factor to Burkitt’s lymphomas. Proc Natl Acad Sci U S A 100: 14269–14274. doi: 10.1073/pnas.2336099100 14603034

15. Komano J, Sugiura M, Takada K (1998) Epstein-Barr virus contributes to the malignant phenotype and to apoptosis resistance in Burkitt’s lymphoma cell line Akata. Journal of virology 72: 9150–9156. 9765461

16. Shimizu N, Tanabe-Tochikura A, Kuroiwa Y, Takada K (1994) Isolation of Epstein-Barr virus (EBV)-negative cell clones from the EBV-positive Burkitt’s lymphoma (BL) line Akata: malignant phenotypes of BL cells are dependent on EBV. Journal of virology 68: 6069–6073. 8057484

17. Vereide D, Sugden B (2009) Proof for EBV’s sustaining role in Burkitt’s lymphomas. Semin Cancer Biol 19: 389–393. doi: 10.1016/j.semcancer.2009.07.006 19628040

18. Cai X, Schafer A, Lu S, Bilello JP, Desrosiers RC, et al. (2006) Epstein-Barr virus microRNAs are evolutionarily conserved and differentially expressed. PLoS pathogens 2: e23. doi: 10.1371/journal.ppat.0020023 16557291

19. Chen SJ, Chen GH, Chen YH, Liu CY, Chang KP, et al. (2010) Characterization of Epstein-Barr virus miRNAome in nasopharyngeal carcinoma by deep sequencing. PloS one 5.

20. Grundhoff A, Sullivan CS, Ganem D (2006) A combined computational and microarray-based approach identifies novel microRNAs encoded by human gamma-herpesviruses. RNA 12: 733–750. doi: 10.1261/rna.2326106 16540699

21. Pfeffer S, Zavolan M, Grasser FA, Chien M, Russo JJ, et al. (2004) Identification of virus-encoded microRNAs. Science 304: 734–736. doi: 10.1126/science.1096781 15118162

22. Qiu J, Cosmopoulos K, Pegtel M, Hopmans E, Murray P, et al. (2011) A novel persistence associated EBV miRNA expression profile is disrupted in neoplasia. PLoS pathogens 7: e1002193. doi: 10.1371/journal.ppat.1002193 21901094

23. Zhu JY, Pfuhl T, Motsch N, Barth S, Nicholls J, et al. (2009) Identification of novel Epstein-Barr virus microRNA genes from nasopharyngeal carcinomas. Journal of virology 83: 3333–3341. doi: 10.1128/JVI.01689-08 19144710

24. Cosmopoulos K, Pegtel M, Hawkins J, Moffett H, Novina C, et al. (2009) Comprehensive profiling of Epstein-Barr virus microRNAs in nasopharyngeal carcinoma. Journal of virology 83: 2357–2367. doi: 10.1128/JVI.02104-08 19091858

25. Vereide DT, Seto E, Chiu YF, Hayes M, Tagawa T, et al. (2013) Epstein-Barr virus maintains lymphomas via its miRNAs. Oncogene.

26. Choy EY, Siu KL, Kok KH, Lung RW, Tsang CM, et al. (2008) An Epstein-Barr virus-encoded microRNA targets PUMA to promote host cell survival. The Journal of experimental medicine 205: 2551–2560. doi: 10.1084/jem.20072581 18838543

27. Riley KJ, Rabinowitz GS, Yario TA, Luna JM, Darnell RB, et al. (2012) EBV and human microRNAs co-target oncogenic and apoptotic viral and human genes during latency. The EMBO journal 31: 2207–2221. doi: 10.1038/emboj.2012.63 22473208

28. Lei T, Yuen KS, Xu R, Tsao SW, Chen H, et al. (2013) Targeting of DICE1 tumor suppressor by Epstein-Barr virus-encoded miR-BART3* microRNA in nasopharyngeal carcinoma. International journal of cancer Journal international du cancer 133: 79–87. doi: 10.1002/ijc.28007 23280823

29. Marquitz AR, Mathur A, Nam CS, Raab-Traub N (2011) The Epstein-Barr Virus BART microRNAs target the pro-apoptotic protein Bim. Virology 412: 392–400. doi: 10.1016/j.virol.2011.01.028 21333317

30. Smith PA, Merritt D, Barr L, Thorley-Lawson DA (2011) An orthotopic model of metastatic nasopharyngeal carcinoma and its application in elucidating a therapeutic target that inhibits metastasis. Genes & cancer 2: 1023–1033. doi: 10.1177/1947601912440878 22737268

31. Kudo-Saito C, Shirako H, Takeuchi T, Kawakami Y (2009) Cancer metastasis is accelerated through immunosuppression during Snail-induced EMT of cancer cells. Cancer Cell 15: 195–206. doi: 10.1016/j.ccr.2009.01.023 19249678

32. de Herreros AG, Peiro S, Nassour M, Savagner P (2010) Snail family regulation and epithelial mesenchymal transitions in breast cancer progression. J Mammary Gland Biol Neoplasia 15: 135–147. doi: 10.1007/s10911-010-9179-8 20455012

33. Wang Y, Shi J, Chai K, Ying X, Zhou BP (2013) The Role of Snail in EMT and Tumorigenesis. Curr Cancer Drug Targets 13: 963–972. doi: 10.2174/15680096113136660102 24168186

34. Yates JL, Guan N (1991) Epstein-Barr virus-derived plasmids replicate only once per cell cycle and are not amplified after entry into cells. Journal of virology 65: 483–488. 1845903

35. Cuomo L, Ramquist T, Trivedi P, Wang F, Klein G, et al. (1992) Expression of the Epstein-Barr virus (EBV)-encoded membrane protein LMP1 impairs the in vitro growth, clonability and tumorigenicity of an EBV-negative Burkitt lymphoma line. International journal of cancer Journal international du cancer 51: 949–955. doi: 10.1002/ijc.2910510619 1322379

36. Walter J, Moller P, Moldenhauer G, Schirrmacher V, Pawlita M, et al. (1992) Local growth of a Burkitt’s lymphoma versus disseminated invasive growth of the autologous EBV-immortalized lymphoblastoid cells and their somatic cell hybrids in SCID mice. International journal of cancer Journal international du cancer 50: 265–273. doi: 10.1002/ijc.2910500217 1309726

37. Man CH, Wei-Man Lun S, Wai-Ying Hui J, To KF, Choy KW, et al. (2012) Inhibition of NOTCH3 signalling significantly enhances sensitivity to cisplatin in EBV-associated nasopharyngeal carcinoma. The Journal of pathology 226: 471–481. doi: 10.1002/path.2997 22009689

38. Angiolillo AL, Sgadari C, Sheikh N, Reaman GH, Tosato G (1995) Regression of experimental human leukemias and solid tumors induced by Epstein-Barr virus-immortalized B cells. Leukemia & lymphoma 19: 267–276. doi: 10.3109/10428199509107897 8535218

39. Ghetie MA, Richardson J, Tucker T, Jones D, Uhr JW, et al. (1990) Disseminated or localized growth of a human B-cell tumor (Daudi) in SCID mice. International journal of cancer Journal international du cancer 45: 481–485. doi: 10.1002/ijc.2910450318 2307538

40. Zhang C, Awasthi N, Schwarz MA, Schwarz RE (2013) Establishing a peritoneal dissemination xenograft mouse model for survival outcome assessment of experimental gastric cancer. The Journal of surgical research 182: 227–234. doi: 10.1016/j.jss.2012.10.052 23201270

41. von Kalle C, Wolf J, Becker A, Sckaer A, Munck M, et al. (1992) Growth of Hodgkin cell lines in severely combined immunodeficient mice. International journal of cancer Journal international du cancer 52: 887–891. doi: 10.1002/ijc.2910520610 1459730

42. Robertson ES, Tomkinson B, Kieff E (1994) An Epstein-Barr virus with a 58-kilobase-pair deletion that includes BARF0 transforms B lymphocytes in vitro. Journal of virology 68: 1449–1458. 8107208

43. Kempkes B, Pich D, Zeidler R, Sugden B, Hammerschmidt W (1995) Immortalization of human B lymphocytes by a plasmid containing 71 kilobase pairs of Epstein-Barr virus DNA. Journal of virology 69: 231–238. 7983714

44. Klinke O, Feederle R, Delecluse HJ (2014) Genetics of Epstein-Barr virus microRNAs. Semin Cancer Biol 26C: 52–59. doi: 10.1016/j.semcancer.2014.02.002 24602823

45. Darekar S, Georgiou K, Yurchenko M, Yenamandra SP, Chachami G, et al. (2012) Epstein-Barr virus immortalization of human B-cells leads to stabilization of hypoxia-induced factor 1 alpha, congruent with the Warburg effect. PLoS One 7: e42072. doi: 10.1371/journal.pone.0042072 22848707

46. Murono S, Inoue H, Tanabe T, Joab I, Yoshizaki T, et al. (2001) Induction of cyclooxygenase-2 by Epstein-Barr virus latent membrane protein 1 is involved in vascular endothelial growth factor production in nasopharyngeal carcinoma cells. Proc Natl Acad Sci U S A 98: 6905–6910. doi: 10.1073/pnas.121016998 11381123

47. Sakakibara S, Tosato G (2009) Regulation of angiogenesis in malignancies associated with Epstein-Barr virus and Kaposi’s sarcoma-associated herpes virus. Future Microbiol 4: 903–917. doi: 10.2217/fmb.09.49 19722843

48. Wakisaka N, Kondo S, Yoshizaki T, Murono S, Furukawa M, et al. (2004) Epstein-Barr virus latent membrane protein 1 induces synthesis of hypoxia-inducible factor 1 alpha. Mol Cell Biol 24: 5223–5234. doi: 10.1128/MCB.24.12.5223-5234.2004 15169887

49. Wakisaka N, Murono S, Yoshizaki T, Furukawa M, Pagano JS (2002) Epstein-barr virus latent membrane protein 1 induces and causes release of fibroblast growth factor-2. Cancer Res 62: 6337–6344. 12414666

50. Qiu J, Cosmopoulos K, Pegtel M, Hopmans E, Murray P, et al. (2011) A novel persistence associated EBV miRNA expression profile is disrupted in neoplasia. PLoS Pathog 7: e1002193. doi: 10.1371/journal.ppat.1002193 21901094

51. Hochberg D, Souza T, Catalina M, Sullivan JL, Luzuriaga K, et al. (2004) Acute infection with Epstein-Barr virus targets and overwhelms the peripheral memory B-cell compartment with resting, latently infected cells. J Virol 78: 5194–5204. doi: 10.1128/JVI.78.10.5194-5204.2004 15113901

52. Partridge J, Flaherty P (2009) An in vitro FluoroBlok tumor invasion assay. Journal of visualized experiments: JoVE. doi: 10.3791/1475 19620957

Štítky
Hygiena a epidemiológia Infekčné lekárstvo Laboratórium

Článok vyšiel v časopise

PLOS Pathogens


2015 Číslo 1
Najčítanejšie tento týždeň
Najčítanejšie v tomto čísle
Kurzy

Zvýšte si kvalifikáciu online z pohodlia domova

Eozinofilní granulomatóza s polyangiitidou
nový kurz

Betablokátory a Ca antagonisté z jiného úhlu
Autori: prof. MUDr. Michal Vrablík, Ph.D., MUDr. Petr Janský

Autori: doc. MUDr. Petr Čáp, Ph.D.

Farmakoterapie akutní a chronické bolesti

Získaná hemofilie - Povědomí o nemoci a její diagnostika

Všetky kurzy
Prihlásenie
Zabudnuté heslo

Nemáte účet?  Registrujte sa

Zabudnuté heslo

Zadajte e-mailovú adresu, s ktorou ste vytvárali účet. Budú Vám na ňu zasielané informácie k nastaveniu nového hesla.

Prihlásenie

Nemáte účet?  Registrujte sa